Fund prospectus, KIID and/or offering documents before making investment decisions.

# Wellington Strategic European Equity Fund



**EUR S Accumulating Unhedged** 

#### **RISK AND REWARD PROFILE**

1 2 3 4 5 6 7
Lowest Risk Highest Risk

Capital at risk: please refer to the bottom of this page for details about the Risk & Reward Profile.

#### MORNINGSTAR™ RATING\*: ★★★★

#### **FUND DETAILS\***

Fund Inception: December 2011 Share Class Inception: December 2011 Fund Assets: EUR 1.5 billion NAV: EUR 33.59

\*This fund is no longer accepting new investors and may have restrictions on additional investment. Please contact your Wellington relationship manager prior to making additional subscriptions.

#### **KEY INFORMATION**

Domicile: Ireland

Regulatory Regime: UCITS

Legal Structure: Public Limited Company

**Dealing Frequency**: Daily

Country Registration: Austria, Chile, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Singapore \*, Spain, Sweden,

Switzerland, United Kingdom. ISIN: IE00B6TYHG95

Bloomberg: WSEEAUH ID Sedol: B6TYHG9 Lipper: 68139261 WKN: A1JRCV \*Restricted scheme

## **FUND CHARACTERISTICS**

Asset-Weighted Market
Capitalisation:

EUR 31.0 billion

 Beta (3 Yr):
 1.00

 Tracking Risk (3 Yr, Annualised):
 3.3%

 Turnover:
 43.5%

## **FEES AND PRICING**

Minimum Investment: USD 1 million Management Fee: 0.70% p.a. Ongoing Charges Figure\*: 0.79%

The Ongoing Charges Figure represents all annual expenses and additional charges taken from the fund. A more detailed description of the charges that apply to the Fund is set out in the section "Charges of the Umbrella Fund" in the Prospectus. The ongoing charges figure may change over time. Charges applied will reduce the return potential of investments.

Charges applied will reduce the return potential of investments

For more information, please visit **www.wellingtonfunds.com** 

### SUMMARY OF INVESTMENT OBJECTIVE

The Wellington Strategic European Equity Fund seeks long-term total returns in excess of the the MSCI Europe Index. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of predominantly European-domiciled companies that are believed to benefit from earnings and cash flow growth that are greater than the market average.


#### **FUND PERFORMANCE (%)**

Past performance does not predict future returns.

#### TOTAL RETURNS NET OF FEES AND EXPENSES

	YTD	1 MO	3 MOS	1 YR	3 YRS	5 YRS	10 YRS
EUR S Acc	-4.4	-2.5	1.4	16.5	12.8	8.5	11.0
MSCI Europe Net	-6.1	-3.0	-0.9	15.4	9.0	6.6	8.1

# **CALENDAR YEAR RETURNS**



#### **DISCRETE ANNUAL PERFORMANCE**

MAR '21 - MAR '20 - MAR '19 - MAR '18 - MAR '17 - MAR '16 - MAR '15 - MAR '14 - MAR '13 - MAR '12 - FEB '22 FEB '21 FEB '20 FEB '19 FEB '18 FEB '17 FEB '16 FEB '15 FEB '14 FEB '13

EUR S Acc	16.5	13.7	8.3	-3.0	8.1	15.0	-3.5	23.8	14.2	20.3
MSCI Europe Net	15.4	8.9	3.0	1.3	5.0	14.7	-13.4	19.0	18.8	12.7

# Past results are not necessarily indicative of future results and an investment can lose value.

The inception date of the EUR S Acc share class is 15 December 2011. | Periods greater than one year are annualised. | If an investor's own currency is different from the currency in which the fund is denominated, the investment return may increase or decrease as a result of currency fluctuations. | Fund returns shown are net of EUR S Acc share class fees and expenses. Fund returns shown are net of actual (but not necessarily maximum) withholding and capital gains tax but are not otherwise adjusted for the effects of taxation and assume reinvestment of dividends and capital gains. The index returns, where applicable, are shown net of maximum withholding tax and assume reinvestment of dividends. | Please note the fund has a swing pricing mechanism in place. | If the last business day of the month is not a business day for the Fund, performance is calculated using the last available NAV. This may result in a performance differential between the fund and the index. | Source: Fund - Wellington Management. Index - MSCI.

#### **FUND MANAGEMENT**



Wellington Management Company LLP (WMC) is an independently owned investment adviser registered with the US Securities and Exchange Commission. WMC, along with its affiliates (collectively, Wellington Management), provides investment management and investment advisory services to institutions around the world. | This material and its contents may not be reproduced or distributed, in whole or in part, without the express written consent of Wellington Management MARKETING COMMUNICATION. Nothing in this document should be interpreted as advice, nor is it a recommendation to buy or sell shares in Wellington Management Funds (Ireland) plc (the Fund. Investment in the Fund may not be suitable for all investors. The Fund only accepts professional clients or investment through financial intermediaries. Fund shares are made available only in jurisdictions where such offer or solicitation is lawful. Please read the latest Key Investor Information Document (KIID) Prospectus, and latest annual report (and semi-annual report) before investing. For each country where the Fund is registered for sale, the prospectus, complaints procedure and summary of investor rights in English, and the KIID in English and an official language, are available from the Funds Transfer Agent to the Complaints Officer at the address of the Funds Transfer Agent to the Wellington Global TA@statestreet.com. The Fund is authorised and regulated as a UCITS scheme by the Central Bank of Ireland. The Fund and address of the Funds Transfer Agent to the world in the Funds Transfer Agent to the Complaints Officer at the Com

#### WHAT ARE THE RISKS?

CAPITAL: Investment markets are subject to economic, regulatory, market sentiment and political risks. All investors should consider the risks that may impact their capital, before investing. The value of your investment may become worth more or less than at the time of the original investment. The Fund may experience a high volatility from time to time.

**CONCENTRATION:** Concentration of investments within securities, sectors or industries, or geographical regions may impact performance.

CURRENCY: The value of the Fund may be affected by changes in currency exchange rates. Unhedged currency risk may subject the Fund to significant volatility.

**EMERGING MARKETS:** Emerging markets may be subject to custodial and political risks, and volatility. Investment in foreign currency entails exchange risks.

EQUITIES: Investments may be volatile and may fluctuate according to market conditions, the performance of individual companies and that of the broader equity market.

**HEDGING:** Any hedging strategy using derivatives may not achieve a perfect hedge.

MANAGER: Investment performance depends on the investment management team and their investment strategies. If the strategies do not perform as expected, if opportunities to implement them do not arise, or if the team does not implement its investment strategies successfully; then a fund may underperform or experience losses.

SMALL AND MID-CAP COMPANY: Small and mid-cap companies' valuations may be more volatile than those of large cap companies. They may also be less liquid.

SUSTAINABILITY RISK: A Sustainability Risk can be defined as an environmental, social or governance event or condition that, if it occurs, could cause an actual or potential material negative impact on the value of an investment.

Before subscribing, please refer to the Fund offering documents/prospectus for further risk factors and pre-investment disclosures. For the latest NAV, please visit www.fundinfo.com.


#### **GEOGRAPHIC BREAKDOWN**

# % OF EQUITY 38.2 United Kingdom 16.3 13 1 17.8 Sweden Switzerland Belgium 1.4 31 Austria Netherlands 1.7 0 10 20 30 40

# Totals may not add up to 100% due to rounding.

Benchmark

## SECTOR DISTRIBUTION



Totals may not add up to 100% due to rounding.

#### **TOP 10 HOLDINGS**

Fund

COMPANY NAME	MARKET	INDUSTRY	% OF EQUITY
Novartis AG	Switzerland	Pharma, Biotech & Life Sciences	4.6
British-Amer Tobacco	United Kingdom	Food Beverage & Tobacco	4.0
GlaxoSmithKline Plc	United Kingdom	Pharma, Biotech & Life Sciences	3.9
UCB SA	Belgium	Pharma, Biotech & Life Sciences	3.9
UBS Group AG	Switzerland	Diversified Financials	3.3
BAE Systems PLC	United Kingdom	Capital goods	3.3
Bunzl PLC	United Kingdom	Capital goods	3.2
Safran SA	France	Capital goods	3.1
Swedish Match AB	Sweden	Food Beverage & Tobacco	3.1
Fresenius SE & Co	Germany	Health Care Equipment & Services	3.0
Total of Top 10			35.4
Number of Equity Names			61

The individual issuers listed should not be considered a recommendation to buy or sell. The weightings do not reflect exposure gained through the use of derivatives. Holdings vary and there is no guarantee that the Fund will hold any of the securities listed. Please refer to the annual and semi-annual report for the full holdings.